

Arlene M Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/710990/publications.pdf>

Version: 2024-02-01

29
papers

1,334
citations

516710

16
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

1377
citing authors

#	ARTICLE	IF	CITATIONS
1	Reconsidering scarce drug rationing: implications for clinical research. <i>Journal of Medical Ethics</i> , 2021, 47, e16-e16.	1.8	0
2	Is Real-Time ELSI Realistic?. <i>AJOB Empirical Bioethics</i> , 2020, 11, 134-144.	1.6	6
3	Clarifying a Clinical Ethics Service's Value, the Visible and the Hidden. <i>Journal of Clinical Ethics</i> , 2019, 30, 251-261.	0.3	2
4	“Forward-Thinking” in U.S. Biobanking. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 148-154.	0.7	12
5	Which Results to Return: Subjective Judgments in Selecting Medically Actionable Genes. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 184-194.	0.7	17
6	Transitions in Care for Infants with Trisomy 13 or 18. <i>American Journal of Perinatology</i> , 2017, 34, 887-894.	1.4	11
7	Membership recruitment and training in health care ethics committees: Results from a national pilot survey. <i>AJOB Empirical Bioethics</i> , 2017, 8, 161-169.	1.6	7
8	Response to Open Peer Commentaries on “Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice” <i>American Journal of Bioethics</i> , 2015, 15, W6-W9.	0.9	0
9	Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice. <i>American Journal of Bioethics</i> , 2015, 15, 3-14.	0.9	30
10	Genomic Research with the Newly Dead: A Crossroads for Ethics and Policy. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 220-231.	0.9	8
11	Stewardship Practices of U.S. Biobanks. <i>Science Translational Medicine</i> , 2013, 5, 215cm7.	12.4	34
12	Characterizing biobank organizations in the U.S.: results from a national survey. <i>Genome Medicine</i> , 2013, 5, 3.	8.2	157
13	Addressing “Difficult Patient” Dilemmas: Possible Alternatives to the Mediation Model. <i>American Journal of Bioethics</i> , 2012, 12, 13-14.	0.9	2
14	Trade-Secret Model: Legal Limitations’ Response. <i>Science</i> , 2011, 333, 1575-1576.	12.6	0
15	Parents' Online Portrayals of Pediatric Treatment and Research Options. <i>Journal of Empirical Research on Human Research Ethics</i> , 2009, 4, 73-87.	1.3	8
16	Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging Issues. <i>Pediatrics</i> , 2008, 121, e693-e704.	2.1	92
17	Clinical Trials and Medical Care: Defining the Therapeutic Misconception. <i>PLoS Medicine</i> , 2007, 4, e324.	8.4	376
18	A place for genetic uncertainty: Parents valuing an unknown in the meaning of disease. <i>Social Science and Medicine</i> , 2007, 65, 1082-1093.	3.8	68

#	ARTICLE	IF	CITATIONS
19	The many meanings of care in clinical research. <i>Sociology of Health and Illness</i> , 2006, 28, 695-712.	2.1	60
20	Therapeutic misconception in early phase gene transfer trials. <i>Social Science and Medicine</i> , 2006, 62, 239-253.	3.8	113
21	Changing perspectives on the benefits of newborn screening. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2006, 12, 270-279.	3.6	48
22	Consent Forms and the Therapeutic Misconception: The Example of Gene Transfer Research. <i>IRB: Ethics & Human Research</i> , 2005, 27, 1.	0.8	79
23	Consent forms and the therapeutic misconception: the example of gene transfer research. <i>IRB: Ethics & Human Research</i> , 2005, 27, 1-8.	0.8	30
24	Uncertain benefit: investigators' views and communications in early phase gene transfer trials. <i>Molecular Therapy</i> , 2004, 10, 225-231.	8.2	44
25	Vulnerability to Influence: A Two-Way Street. <i>American Journal of Bioethics</i> , 2004, 4, 50-52.	0.9	18
26	Assessing Benefits in Clinical Research: Why Diversity in Benefit Assessment Can Be Risky. <i>IRB: Ethics & Human Research</i> , 2003, 25, 1.	0.8	26
27	Assessing benefits in clinical research: why diversity in benefit assessment can be risky. <i>IRB: Ethics & Human Research</i> , 2003, 25, 1-8.	0.8	10
28	The Invisible Hand in Clinical Research: The Study Coordinator's Critical Role in Human Subjects Protection. <i>Journal of Law, Medicine and Ethics</i> , 2002, 30, 411-419.	0.9	69
29	Exception from Informed Consent for Emergency Research: Drawing on Existing Skills and Experience. <i>IRB: Ethics & Human Research</i> , 1998, 20, 1.	0.8	7